Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP631622.RAtG6VtNQ0oRX-moSCztf2s26F5AfjJul-5jGNy-K8VA8130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP631622.RAtG6VtNQ0oRX-moSCztf2s26F5AfjJul-5jGNy-K8VA8130_assertion type Assertion NP631622.RAtG6VtNQ0oRX-moSCztf2s26F5AfjJul-5jGNy-K8VA8130_head.
- NP631622.RAtG6VtNQ0oRX-moSCztf2s26F5AfjJul-5jGNy-K8VA8130_assertion wasGeneratedBy ECO_0000203 NP631622.RAtG6VtNQ0oRX-moSCztf2s26F5AfjJul-5jGNy-K8VA8130_provenance.
- NP631622.RAtG6VtNQ0oRX-moSCztf2s26F5AfjJul-5jGNy-K8VA8130_assertion wasDerivedFrom befree-20150227 NP631622.RAtG6VtNQ0oRX-moSCztf2s26F5AfjJul-5jGNy-K8VA8130_provenance.
- NP631622.RAtG6VtNQ0oRX-moSCztf2s26F5AfjJul-5jGNy-K8VA8130_assertion SIO_000772 15041728 NP631622.RAtG6VtNQ0oRX-moSCztf2s26F5AfjJul-5jGNy-K8VA8130_provenance.
- NP631622.RAtG6VtNQ0oRX-moSCztf2s26F5AfjJul-5jGNy-K8VA8130_assertion evidence source_evidence_literature NP631622.RAtG6VtNQ0oRX-moSCztf2s26F5AfjJul-5jGNy-K8VA8130_provenance.
- NP631622.RAtG6VtNQ0oRX-moSCztf2s26F5AfjJul-5jGNy-K8VA8130_assertion description "[Overexpression of CYR61, CTGF, WISP-1, and NOV occurred in 48% (32 of 66), 58% (38 of 66), 36% (24 of 66), and 15% (10 of 66) of primary gliomas, respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP631622.RAtG6VtNQ0oRX-moSCztf2s26F5AfjJul-5jGNy-K8VA8130_provenance.